Telehealth Narcolepsy Prescribing: What PMHNPs Can Do in Georgia

You trained for years to help patients manage complex conditions. You’re watching patients with narcolepsy struggle to stay awake during the day, lose jobs, and sometimes endanger themselves behind the wheel—all while waiting months to see a sleep specialist who may or may not have availability. Meanwhile, you have the clinical expertise and full prescriptive authority to help, but you’re navigating a maze of DEA rules, state telehealth laws, and questions about whether you can even prescribe stimulants remotely.

Here’s the reality: psychiatrists are uniquely positioned to manage narcolepsy via telehealth, especially when sleep specialists are scarce. You can diagnose, prescribe first-line treatments (including Schedule II stimulants), and provide ongoing medication management—all from a video visit. But the rules keep changing, state laws vary wildly, and you need clarity on what’s actually legal and practical in 2026.

This guide cuts through the confusion. We’ll cover your full scope of practice for narcolepsy prescribing, current federal telehealth allowances, state-specific restrictions, and the real workflow for managing these patients remotely. Whether you’re considering telehealth, already practicing, or just want to understand your options for treating underserved narcolepsy patients, you’ll walk away knowing exactly what you can do—and how platforms like Klarity Health make it simpler.

Your Authority: What Psychiatrists Can Actually Prescribe for Narcolepsy

As a board-certified psychiatrist (MD or DO), you have full prescriptive authority for narcolepsy medications in every state. That includes:

• Schedule II stimulants: Amphetamine (Adderall), methylphenidate (Ritalin, Concerta), dextroamphetamine
• Schedule IV wake-promoting agents: Modafinil (Provigil), armodafinil (Nuvigil)
• Newer wakefulness medications: Solriamfetol (Sunosi), pitolisant (Wakix)
• Sodium oxybate (Xyrem/Xywav): For narcolepsy with cataplexy (requires REMS enrollment)
• Adjunct medications: Antidepressants for cataplexy (SSRIs, SNRIs), nighttime sedatives if needed

Unlike nurse practitioners, who face state-by-state prescribing restrictions (we’ll cover that below), your MD/DO license gives you categorical authority to prescribe controlled substances. The limitations you face aren’t about scope—they’re about telehealth-specific rules and DEA regulations that apply equally to all prescribers.

Narcolepsy vs. ADHD: Similar Meds, Different Clinical Picture

If you already manage ADHD via telehealth, narcolepsy medication management will feel familiar—you’re prescribing many of the same stimulants. But there are key differences:

• Higher doses: Narcolepsy patients often need higher stimulant doses than ADHD patients to combat excessive daytime sleepiness
• Unique dosing schedules: Many take a morning dose plus an early afternoon dose to prevent mid-day sleep attacks
• Polypharmacy is common: Patients may be on a stimulant for wakefulness plus a sedative at night (if using sodium oxybate) or an antidepressant for cataplexy
• Diagnosis requires sleep studies: Unlike ADHD where you can diagnose clinically, narcolepsy diagnosis typically requires polysomnography and a multiple sleep latency test (MSLT) from a sleep specialist. You’ll often be managing patients with an established diagnosis rather than making the initial diagnosis yourself.

Most telehealth psychiatrists managing narcolepsy work collaboratively: a sleep specialist confirms the diagnosis and orders testing, you handle the ongoing medication management and dose adjustments. This division of labor works well in shortage areas where sleep specialists are booked months out but patients need consistent medication monitoring.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Telehealth Rules: What’s Legal in 2026

The biggest question: Can you prescribe Schedule II stimulants via telehealth without seeing the patient in person?

As of 2026, yes—for now. Here’s the timeline:

The Ryan Haight Act (Pre-COVID Baseline)

Before 2020, federal law (the Ryan Haight Act) required an in-person medical evaluation before prescribing controlled substances via telemedicine. There were narrow exceptions (established patient relationships, certain facility-to-facility consults), but generally you couldn’t start Adderall or other Schedule IIs remotely.

COVID-Era Flexibilities (2020–2025)

In March 2020, the DEA issued emergency waivers suspending the in-person requirement during the Public Health Emergency. This allowed psychiatrists to prescribe controlled substances, including Schedule II stimulants, after a video (audio-visual) evaluation without ever meeting the patient face-to-face.

Extended Through 2025 (Current Status)

In November 2024, the DEA and HHS extended these telehealth flexibilities through at least December 31, 2025. This means you can currently:

• Conduct initial evaluations via video
• Prescribe Schedule II–V controlled substances (including Adderall, Ritalin, modafinil) based solely on that telehealth visit
• Continue treating patients entirely remotely as long as you maintain proper documentation and standard of care

Important caveat: After 2025, the rules may revert or evolve. The DEA has proposed requiring a ‘telemedicine DEA registration’ or mandating at least one in-person visit within a timeframe (e.g., 30 days of initial prescription). As of early 2026, those proposals aren’t finalized. Stay alert for updates from the DEA, and consider platform solutions (like Klarity Health) that monitor regulatory changes and help you adapt quickly.

What This Means Practically

Right now, you can:

1. Evaluate a new narcolepsy patient via secure video (audio-visual required—no phone-only initial visits)
2. Review their sleep study documentation (uploaded to your EHR or platform)
3. Prescribe a Schedule II stimulant (e.g., 30-day supply of Adderall XR) after that visit
4. Manage ongoing care remotely with monthly or quarterly follow-ups via video

You must be licensed in the patient’s state and have a valid DEA registration. You’ll also need to use electronic prescribing of controlled substances (EPCS) since paper prescriptions aren’t practical for telehealth and many states now require e-prescribing for Schedule IIs.

State-Level Telehealth Restrictions: Where It Gets Complicated

Federal law sets a floor, but states can impose additional restrictions. While most states now allow telehealth prescribing of controlled substances in alignment with federal rules, a few have quirky limitations specifically affecting narcolepsy care.

Florida: The Big Exception

Florida law prohibits prescribing Schedule II controlled substances via telehealth unless the patient falls into specific exemptions:

• Psychiatric disorders (ADHD, bipolar disorder, etc.)
• Inpatient/hospital care
• Hospice/palliative care
• Chronic pain management (with special registration)

Here’s the problem: Narcolepsy is a neurological disorder, not a psychiatric disorder. Technically, a Florida-licensed psychiatrist treating narcolepsy cannot prescribe Adderall or other Schedule IIs purely via telehealth under state law—even though federal law allows it.

Workarounds:

• Prescribe non-Schedule II alternatives: Modafinil (Schedule IV) is allowed via telehealth in Florida. Many narcolepsy patients respond well to modafinil, so this is a viable clinical option.
• Comorbid psychiatric diagnosis: If your patient has both narcolepsy and ADHD (common comorbidity), you could potentially prescribe the stimulant for the ADHD diagnosis, which is a psychiatric indication. Legally gray, but some providers use this approach with proper documentation.
• Require one in-person visit: Have the patient see a local physician once for the initial prescription, then manage via telehealth. Not ideal for access but maintains compliance.

Bottom line for Florida: You can manage narcolepsy via telehealth, but you’ll likely use modafinil/armodafinil as your first-line meds rather than amphetamine stimulants, unless the patient has already been started on those by an in-person provider.

Texas: NP Restrictions (But MDs Are Fine)

Texas law limits nurse practitioners/physician assistants from prescribing Schedule II drugs in outpatient settings (they can only do so in hospitals or hospice). However, this does NOT apply to physicians. Texas MDs have full authority to prescribe narcolepsy medications via telehealth.

If you’re a psychiatrist in Texas or treating Texas patients, you’re in the clear. Just ensure you meet Texas Medical Board telemedicine standards (audio-visual visits, proper documentation, standard of care).

New York, California, Illinois, Pennsylvania: Generally Permissive

These states have no additional barriers beyond federal rules for physician prescribing of controlled substances via telehealth:

• New York: Requires checking the I-STOP PDMP database before each controlled prescription. Telehealth parity laws ensure you’re reimbursed the same as in-person.
• California: Requires checking the CURES PDMP. Telehealth fully supported; no special restrictions on Schedule II prescribing.
• Illinois: Allows telehealth prescribing in line with federal rules. Requires PDMP checks. Payment parity mandated by state law.
• Pennsylvania: No state-specific prohibition on tele-prescribing Schedule IIs for physicians. Must follow Board of Medicine telemedicine guidelines (establish proper patient relationship, maintain records).

In these states, you can practice narcolepsy medication management via telehealth with the same authority as in-person.

The Common Thread: PDMP Checks Are Mandatory

Almost every state now requires prescribers to check the state prescription drug monitoring program (PDMP) before prescribing controlled substances:

• Before every Schedule II prescription in many states (New York, California)
• Before initial prescription and periodically in others (check your state’s specific rules)

This is non-negotiable and adds 2–3 minutes to each encounter. Most telehealth platforms integrate PDMP access into the workflow so you can check in real-time during the visit.

The Clinical Workflow: Managing Narcolepsy Remotely

Here’s what narcolepsy medication management actually looks like in a telehealth practice:

Initial Evaluation (45–60 minutes)

Prerequisites: Patient has narcolepsy diagnosis confirmed by sleep specialist (polysomnography + MSLT showing shortened sleep latency and/or REM intrusions). Review uploaded sleep study reports.

Visit components:

1. History: Symptom onset, frequency of sleep attacks, presence of cataplexy, impact on daily function (work, driving), previous treatments
2. Comorbidities: Screen for depression (common in narcolepsy), anxiety, ADHD, sleep apnea
3. Medical screening: Blood pressure, heart rate (if patient has home monitor), history of cardiovascular disease, substance use
4. Medication history: Prior stimulants, response, side effects, any current medications
5. PDMP check: Required in most states before prescribing
6. Discussion: Medication options, expected benefits/side effects, dosing schedule, safety (no driving if excessively sleepy, avoid alcohol especially with sodium oxybate)
7. Informed consent: Document discussion of controlled substance risks, treatment plan, follow-up schedule

First prescription: Often start with modafinil 200 mg QAM (Schedule IV, lower abuse potential, good efficacy) or a low-dose stimulant like methylphenidate 10 mg BID if modafinil previously ineffective.

Billing: Typically 99204 or 99205 (new patient E/M, 45–60 min)

Follow-Up Visits (15–20 minutes, monthly initially)

Schedule: Monthly for first 3 months during titration, then quarterly for stable patients

Components:

1. Symptom update: Epworth Sleepiness Scale score (quantifies daytime sleepiness), frequency of sleep attacks, any cataplexy episodes
2. Side effect check: Appetite suppression, insomnia, blood pressure changes, mood changes
3. Adherence: Are they taking medication as prescribed? Any pharmacy access issues?
4. PDMP check: Required each visit in most states for Schedule II
5. Dose adjustment: Titrate up if inadequate symptom control (e.g., modafinil 200 mg → 400 mg, or split amphetamine dosing AM + early afternoon)
6. Refill: E-prescribe 30-day supply (Schedule IIs cannot have refills, so monthly prescribing is standard)

Billing: 99213 or 99214 (established patient, problem-focused)

Special Considerations

Sodium oxybate (Xyrem/Xywav): If patient has narcolepsy with cataplexy and hasn’t responded adequately to stimulants alone, sodium oxybate may be needed. This is a restricted distribution drug:

• Requires REMS enrollment: You must register with the Xyrem/Xywav REMS program (one-time, online)
• Single central pharmacy: Patient can only get medication from the specialty pharmacy (Jazz Pharmaceuticals)
• Significant prior authorization: Insurance almost always requires PA with sleep study documentation
• Telehealth-compatible: You can manage this remotely, but expect extra administrative time

Lab monitoring: Generally not required for stimulants, but if using high doses or patient has hypertension, periodic labs (metabolic panel, lipid panel) and BP checks are prudent. Coordinate with patient’s PCP or have patient use home monitoring devices.

Driving safety: Document discussions about not driving if experiencing excessive sleepiness. Some states require physicians to report unsafe drivers (rare, but know your state’s law). Most narcolepsy patients on effective treatment can drive safely, but it’s a key counseling point.

Reimbursement: What You’ll Actually Get Paid

Narcolepsy medication management is financially viable via telehealth, especially with parity laws now in place in most states.

Insurance Reimbursement Rates

Initial visit (99204/99205): $150–$250 depending on payer and region

Follow-up visits (99213/99214): $80–$140 per visit

Annual revenue per narcolepsy patient (assuming monthly visits for 3 months, then quarterly):

• 1 initial visit: ~$200
• 3 monthly follow-ups: ~$300
• 4 quarterly follow-ups (ongoing): ~$400
• Total year 1: ~$900–$1,000 per patient
• Ongoing years: ~$400–$500 per patient annually

If you manage a panel of 50 narcolepsy patients, that’s $20,000–$25,000 annually in recurring revenue just from this subspecialty, with visits that are brief (15–20 min) and structured.

Telehealth Payment Parity

Many states now mandate equal reimbursement for telehealth and in-person visits:

• California, New York, Illinois: Commercial payers must pay the same rate
• Medicare: Currently reimburses telehealth mental health visits at parity (extended through at least 2024, likely beyond)
• Medicaid: Varies by state, but most cover tele-psychiatry at parity

Medicare note: If treating Medicare patients, be aware of potential future rules requiring periodic in-person visits (proposed for post-2024, not yet enforced as of 2026). Monitor CMS updates.

The Reimbursement Gap (And Why Platforms Help)

One frustration: mental health providers are paid ~22% less by private insurers compared to other specialists for equivalent services. This has driven many psychiatrists out-of-network. Narcolepsy care sometimes codes under neurology (ICD-10 G47.4x), which might get processed as a medical benefit rather than behavioral health—potentially avoiding some of that disparity. But don’t count on it.

Platform advantage: Platforms like Klarity Health contract directly with insurers and handle billing/collections, often securing better reimbursement rates than solo practitioners. You see patients, we handle the revenue cycle. No chasing down unpaid claims or dealing with prior auth bureaucracy (though we can’t eliminate PAs entirely—they’re a reality for expensive narcolepsy meds).

Cash-Pay Alternative

Given insurance hassles, some psychiatrists offer self-pay narcolepsy management:

• Initial visit: $300–$400
• Follow-ups: $100–$150

Many narcolepsy patients are willing to pay out-of-pocket for access to a knowledgeable provider who can see them within days rather than months. In underserved areas (rural states, provider shortage regions), this model works well. Platforms can support both insurance and cash-pay, giving you flexibility.

The Administrative Burden (And How to Minimize It)

Let’s be honest: controlled substance prescribing involves red tape.

Prior Authorizations

Reality check: Modafinil, Sunosi, Wakix, and sodium oxybate almost always require prior authorization. You’ll spend 20–40 minutes per patient on forms, peer-to-peer calls, and documentation.

Mitigation strategies:

• Work with a platform that has dedicated PA support staff (Klarity Health assigns this to our team so you focus on clinical care)
• Use step therapy smartly: Start with generic modafinil (fewer PA requirements than newer agents)
• Maintain thorough documentation: Upload sleep study results, note previous treatment failures—makes PAs faster

PDMP Checks

Time cost: 2–3 minutes per visit (if integrated into your EHR/platform), up to 10 minutes if you’re logging into a separate state portal manually

Best practice: Use a telehealth platform with PDMP integration so you can check in real-time during the video visit. Many states now offer API access for EHRs.

EPCS (Electronic Prescribing of Controlled Substances)

You cannot write paper prescriptions for narcolepsy patients in another state (they’d have to travel to pick it up, defeating the purpose of telehealth). You need EPCS.

Requirements:

• DEA registration
• Two-factor authentication for e-prescribing (often a token or mobile app)
• EPCS-certified software (most telehealth platforms provide this—verify before joining)

Cost: Usually included in platform fees or ~$50–$100/year for standalone EPCS certification

The Medication Shortage Wildcard

Since mid-2022, ongoing Adderall shortages have created headaches for providers. Patients call frantically when pharmacies can’t fill prescriptions. You end up writing alternative scripts (switching amphetamine to methylphenidate, or vice versa), spending extra time coordinating with pharmacies, and managing patient distress.

By early 2024, shortages persisted despite DEA/FDA efforts to increase quotas. Platform advantage: We maintain pharmacy networks and can route prescriptions to pharmacies with stock, reducing your time spent troubleshooting.

PMHNP vs. Psychiatrist: Why Your MD Matters Here

If you’re wondering whether nurse practitioners can do this work, the short answer: it depends on the state, and often they cannot—at least not independently.

Key PMHNP Limitations (State Examples)

Bottom line: In restrictive states like Texas and Florida, you need a psychiatrist to fully manage narcolepsy. NPs can assist or manage with physician oversight, but they cannot independently prescribe the first-line treatments (Schedule II stimulants).

Platforms serving these states require physician involvement. If you’re an MD, this is job security—and your scope of practice is the differentiator that allows patients to access care.

Why Join a Telehealth Platform vs. Going Solo

You could manage narcolepsy patients independently—set up your own EHR, credentialing, EPCS, PDMP access, malpractice coverage, and market yourself. Or you could join a platform that handles all of that.

What Platforms Like Klarity Health Provide

Patient acquisition (the expensive part): Acquiring a qualified psychiatric patient through DIY marketing realistically costs $200–$500+ when you factor in:

• SEO (6–12 months before meaningful traffic, ongoing $2,000–$5,000/month in content/optimization)
• Google Ads ($15–$40 per click for mental health keywords; maybe 5–10% convert to booked appointments = $200–$400+ per booked patient)
• Directory listings (Psychology Today, Zocdoc: $100–$300/month subscription + per-booking fees)
• Staff time to handle leads, qualify patients, manage no-shows
• Failed campaigns and testing periods

Klarity’s model: You pay a standard listing fee per new patient appointment—only when a qualified patient books with you. No upfront marketing spend, no monthly subscription, no wasted ad budget. We handle:

• Patient matching (pre-qualified patients already seeking narcolepsy care)
• Scheduling and calendar management
• Insurance verification
• Built-in telehealth platform (video, EPCS, PDMP integration)
• Both insurance and cash-pay patient flow
• Credentialing support across multiple states

Economic reality: Instead of gambling $3,000–$5,000/month on marketing with uncertain results, you pay only when you see patients. Guaranteed ROI vs. risky DIY marketing spend.

Infrastructure:

• EPCS-enabled e-prescribing
• EHR with integrated PDMP access
• HIPAA-compliant video platform
• Prior authorization support staff (we help with PA paperwork)
• Billing and collections (we handle insurance claims, you get paid)

Multistate licensing support: We help streamline applications for licenses in high-demand states (Texas, Florida, California, etc.) so you can see patients nationally and maximize your panel size.

Malpractice coverage: We require you maintain coverage, but many platforms offer group rates or stipends to offset cost.

The Solo Practice Alternative (If You Have Time and Capital)

Going solo works if:

• You have $10,000+ to invest in marketing over 12–18 months before seeing ROI
• You have time to manage your own SEO, Google Ads, and directory presence
• You’re comfortable with billing, coding, and chasing insurance payments
• You can afford staff to handle scheduling, intake, and admin
• You have expertise (or hire a consultant) for telehealth compliance across states

For most providers, especially those starting out or scaling up, the platform model removes the risk and lets you focus on clinical care rather than running a marketing agency.

Narcolepsy Provider FAQ

Can I diagnose narcolepsy via telehealth, or do I need a sleep study?

You can suspect narcolepsy clinically (excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations), but definitive diagnosis requires a sleep study (polysomnography + MSLT). Most telehealth psychiatrists manage patients with a diagnosis already confirmed by a sleep specialist. If you suspect narcolepsy in a patient presenting with fatigue, refer them for testing first—don’t start stimulants empirically without sleep study confirmation (insurance won’t cover meds without documented diagnosis, and you risk missing sleep apnea or other causes).

Do I need to see narcolepsy patients in person at all, or can it be 100% virtual?

Currently (2026), you can manage entirely virtually under extended federal telehealth rules. After December 2025, DEA may reinstate in-person requirements—monitor updates. Even if an in-person rule comes back, it might be ‘one visit within 30 days of starting Schedule II’ or similar—which could be coordinated with a local provider while you continue telehealth follow-ups.

Exception: Florida law currently restricts tele-prescribing of Schedule IIs for narcolepsy (non-psychiatric condition). In FL, you’d need at least one in-person visit by a physician to prescribe Adderall, or use modafinil (Schedule IV) which is allowed via telehealth.

What if a patient is already on Adderall from another provider and wants to transfer care to me via telehealth?

This is common and straightforward. You can continue prescribing an established medication as long as:

• You conduct a full initial evaluation (verify diagnosis, review records, check PDMP)
• The patient has documentation of narcolepsy diagnosis (request sleep study reports)
• You document the medication history and rationale for continuing current regimen

Billing tip: This is still a new patient visit for you (99204/99205 if you’ve never treated them), even though they’re on established therapy.

How do I handle prior authorizations without spending hours on paperwork?

Platform advantage: Klarity Health has dedicated staff who handle PA submissions. You provide clinical notes and diagnosis documentation, we complete forms and do peer-to-peer calls if needed.

If managing solo: Use electronic PA portals (CoverMyMeds, Surescripts) that auto-populate patient data. Keep template letters explaining narcolepsy diagnosis and medical necessity. For drugs like modafinil, most insurers have standard criteria (failed alternatives, sleep study confirmation)—meet those and PAs go through in 24–48 hours.

What about sodium oxybate (Xyrem/Xywav)? Can I prescribe that via telehealth?

Yes, but with extra steps:

1. Enroll in the REMS program (Xyrem/Xywav REMS)—one-time online registration, takes ~20 minutes
2. Patient enrollment: Patient also enrolls in REMS and receives medication only from Jazz Pharmaceuticals’ central pharmacy
3. Prior authorization: Expect this to take 1–2 weeks; requires sleep study documentation and proof of inadequate response to stimulants alone
4. Monthly follow-ups: Sodium oxybate is Schedule III (tightly controlled narcotic), so you’ll do monthly visits initially for safety monitoring (respiratory depression risk, especially if combined with alcohol or sedatives)

Telehealth-compatible: Entire process can be done virtually. Jazz Pharmaceuticals ships medication directly to patient’s home.

What are my malpractice risks for prescribing controlled substances via telehealth?

Main risks (and how to mitigate):

• Diversion/misuse: Check PDMP every visit, document any red flags (early refill requests, lost prescriptions), set clear boundaries in initial visit about controlled substance policy
• Inadequate evaluation: Document thorough history and informed consent. Always review sleep study documentation before starting treatment—never prescribe stimulants for ‘fatigue’ without confirmed narcolepsy diagnosis
• Drug interactions: Review medication list every visit (stimulants + SSRIs = serotonin syndrome risk; stimulants + MAOIs = hypertensive crisis)
• Failure to monitor side effects: Document BP, heart rate discussions (have patient use home monitor if on high-dose stimulants). Screen for mood changes, insomnia, weight loss

Malpractice carriers generally have no issue with telehealth prescribing if you follow standard of care. Maintain thorough documentation, use evidence-based treatment protocols, and ensure your platform/practice has solid HIPAA compliance and secure prescribing systems.

Can I prescribe narcolepsy medications across state lines?

Yes, but you must be licensed in each state where your patients are located. There is no interstate prescribing compact for physicians (unlike some nursing compacts for RNs).

Practical approach:

• Focus on 3–5 high-demand states where you hold or will obtain licenses (e.g., Texas, Florida, California, New York, Illinois—high population, underserved mental health markets)
• Use Interstate Medical Licensure Compact (IMLC) if available—speeds up licensing in 40+ participating states
• Platform support: Klarity Health helps with multistate credentialing and tracks state-specific requirements

Each state license costs $500–$1,500 and takes 30–90 days. Investment pays off: a single license in Texas or California can open access to millions of potential patients.

What’s the patient volume opportunity for narcolepsy?

Narcolepsy prevalence: ~1 in 2,000 (roughly 165,000 Americans), but most are undiagnosed or misdiagnosed as depression/ADHD. Diagnosed patients often struggle to find providers.

Provider shortage: Very few psychiatrists subspecialize in sleep. Most narcolepsy care falls to sleep medicine specialists (neurologists or pulmonologists with sleep fellowship)—and they’re scarce. Over 160 million Americans live in mental health provider shortage areas; sleep specialists are even rarer.

Realistic panel size: A tele-psychiatrist could comfortably manage 50–100 narcolepsy patients as a subspecialty within a broader psychiatric practice (each requires only 15–20 min per visit quarterly once stable). That’s 20–40 patients per week if you dedicated one full day to narcolepsy care.

Revenue potential: 100 patients × $400/year (quarterly follow-ups) = $40,000 annual recurring revenue just from narcolepsy medication management, with low time investment per patient.

Next Steps: Start Treating Narcolepsy Patients via Telehealth

You have the clinical expertise, the prescriptive authority, and now a clear understanding of the legal landscape for treating narcolepsy remotely. The demand is real—patients are waiting months for sleep specialists, struggling to stay awake, and desperate for providers who can manage their medications consistently.

What to do now:

1. Verify your state licenses and identify which states you want to serve (prioritize high-demand, permissive states like California, New York, Illinois, or restricted-but-high-need states like Texas where you’ll use modafinil)
2. Ensure your DEA registration is current and you have EPCS capability
3. Consider a platform vs. building solo practice—platforms like Klarity Health provide pre-qualified patients, infrastructure (EPCS, PDMP integration, billing), and eliminate the $3,000–$5,000/month marketing gamble

Why Klarity Health?

• Pay-per-appointment model: No upfront marketing spend or monthly fees—you pay a standard listing fee only when qualified narcolepsy patients book with you
• Pre-qualified patients: We match patients to your specialty and availability (no wasted time on tire-kickers or no-shows)
• Built-in infrastructure: EPCS-enabled e-prescribing, integrated PDMP access, HIPAA-compliant video, prior auth support
• Insurance and cash-pay: We handle insurance credentialing, billing, and collections—or support cash-pay if you prefer
• Multistate licensing support: We help streamline applications across states so you can maximize your patient panel

Ready to expand your narcolepsy practice via telehealth? Join Klarity Health’s provider network and start seeing patients within weeks. You bring the clinical expertise, we bring the patients and infrastructure.

Join Klarity Health’s Provider Network →

Sources and References

1. Axios – ‘COVID-era telehealth prescribing extended again’ (November 18, 2024). Reports DEA/HHS extension of telehealth controlled-substance allowances through December 31, 2025. Available at: https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

2. Texas Medical Board – FAQ: ‘Who can prescribe Schedule II drugs under physician delegation?’ Official state guidance confirming Texas NP/PA restrictions on Schedule II outpatient prescribing (hospital/hospice only). Available at: https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation

3. California Board of Registered Nursing – AB 890 Implementation (updated 2024). Explains new NP independence pathway (103/104 NP categories) and timeline. Available at: https://www.rn.ca.gov/practice/ab890.shtml

4. Florida Statutes – Section 464.012 (Nurse Practice Act, 2021 compilation). Primary law text showing 7-day Schedule II limit for APRNs and psychiatric nurse exception. Available at: https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All

5. Rivkin Radler Law – ‘New Law Allows Experienced NPs to Practice Independently in NY’ (April 13, 2022). Summary of New York’s 2023 budget law removing collaborative agreement requirement after 3,600 hours. Available at: https://www.rivkinrounds.com/2022/04/new

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority